Breakthrough to Make Bones Stronger Has The Potential to Reverse Osteoporosis
Key Points:
- A first-in-human clinical trial in Spain demonstrated that engineered mesenchymal stem/stromal cells (MSCs) with a bone marrow "return address" significantly reduced fragility fractures by 94% over two years in women over 50 with advanced osteoporosis.
- The trial showed a decrease in fractures from an average of eight per year before treatment to 0.5 per year afterward, along with a 70% increase in bone tissue area and sustained elevation of bone formation markers for six months.
- Participants also reported a 34% reduction in bone pain and a 30% decrease in disability two years post-infusion, suggesting potential reversal of some osteoporosis symptoms rather than just slowing progression.
- Despite promising results, the study lacked a control group and did not track the infused MSCs to confirm their presence in bone, leaving some uncertainty about the exact mechanism behind the improvements.
- A follow-up randomized trial with a larger cohort is underway to compare engineered autologous MSCs, donor MSCs, and no MSC treatment, aiming to validate the efficacy and mechanism of this novel therapy.